Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, including one oral and two poster sessions. The data highlight the potential of two candidates: TNX-1700 and TNX-4700, marking the company's advancement into oncology beyond its established central nervous system (CNS) and immunology focus.
The findings for TNX-1700, a biologic candidate, demonstrated its ability to reduce inflammation and tumor progression in gastric cancer models. Additionally, the compound showed favorable pharmacokinetics, suggesting it could be a viable therapeutic option for gastric cancer, a disease with high unmet medical need. Gastric cancer remains a leading cause of cancer-related deaths globally, and current treatments often have limited efficacy, making new approaches critical.
Separately, TNX-4700, a monoclonal antibody targeting BTLA (B- and T-lymphocyte attenuator), showed promising in vitro activity. BTLA is an immune checkpoint receptor that suppresses T-cell activity, and its inhibition can enhance anti-tumor immune responses. The data supports TNX-4700's potential as a cancer immunotherapy, either as a monotherapy or in combination with other checkpoint inhibitors such as PD-1 or CTLA-4 blockers. This aligns with the broader trend in oncology to combine immunotherapies for improved patient outcomes.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company. Its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), recently approved for fibromyalgia, is the first new treatment for that condition in over 15 years. The company's CNS commercial infrastructure also supports marketed products for acute migraine, including Zembrace SymTouch and Tosymra. Tonix is further exploring TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, while its CNS pipeline includes TNX-2900 for Prader-Willi syndrome.
In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The new oncology data represent a strategic expansion into immuno-oncology, leveraging the company's expertise in biologics and immunology.
According to the press release, the full details of the AACR presentations are available at https://ibn.fm/Oly6o. Investors can find the latest news and updates on TNXP at the company's newsroom: https://ibn.fm/TNXP.
The promising preclinical results for TNX-1700 and TNX-4700 could position Tonix as a contender in the competitive immuno-oncology space, potentially addressing significant unmet needs in gastric cancer and providing a new checkpoint inhibitor option. However, these are still investigational candidates, and further clinical studies are necessary to establish their safety and efficacy.
